Business
Press Release Aug 27 2024
Suven Life Sciences Limited has informed the Exchange regarding a press release dated August 27, 2024, titled "Suven Life Sciences Announces FDA acceptance of Investigational New Drug (IND) and grant of Study may proceed Letter to initiate Phase-1 Clinical Trial of SUVN-I6107, a True Muscarinic M1 Receptor Positive Allosteric Modulator (M1-PAM)".
About this update from Suven Life Sciences Limited
[{"type":"text","content":" Suven Life Sciences Limited has informed the Exchange regarding a press release dated August 27, 2024, titled \"Suven Life Sciences Announces FDA acceptance of Investigational New Drug (IND) and grant of Study may proceed Letter to initiate Phase-1 Clinical Trial of SUVN-I6107, a True Muscarinic M1 Receptor Positive Allosteric Modulator (M1-PAM)\". View Attachment","length":505,"tagName":"div"}]